APA (7th ed.) Citation

Torre, A., Córdova-Gallardo, J., & Munari, A. C. F. (2023). Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier. Therapeutics & Clinical Risk Management, 19, 839. https://doi.org/10.2147/TCRM.S425292

Chicago Style (17th ed.) Citation

Torre, Aldo, Jacqueline Córdova-Gallardo, and Alberto C Frati Munari. "Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier." Therapeutics & Clinical Risk Management 19 (2023): 839. https://doi.org/10.2147/TCRM.S425292.

MLA (9th ed.) Citation

Torre, Aldo, et al. "Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier." Therapeutics & Clinical Risk Management, vol. 19, 2023, p. 839, https://doi.org/10.2147/TCRM.S425292.